Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, U.K.
School of Life Sciences, University of Warwick, Coventry CV4 7AL, U.K.
ACS Synth Biol. 2022 Oct 21;11(10):3207-3215. doi: 10.1021/acssynbio.1c00629. Epub 2022 Sep 9.
Bacteriophages (phages) represent powerful potential treatments against antibiotic-resistant bacterial infections. Antibiotic-resistant bacteria represent a significant threat to global health, with an estimated 70% of infection-causing bacteria being resistant to one or more antibiotics. Developing novel antibiotics against the limited number of cellular targets is expensive and time-consuming, and bacteria can rapidly develop resistance. While bacterial resistance to phage can evolve, bacterial resistance to phage does not appear to spread through lateral gene transfer, and phage may similarly adapt through mutation to recover infectivity. Phages have been identified for all known bacteria, allowing the strain-selective killing of pathogenic bacteria. Here, we re-engineered the phage P2 to alter its tropism toward pathogenic bacteria. Chimeric tail fibers formed between P2 and S16 genes were designed and generated through two approaches: homology- and literature-based. By presenting chimeric P2:S16 fibers on the P2 particle, our data suggests that the resultant phages were effectively detargeted from the native P2 cellular target, lipopolysaccharide, and were instead able to infect via the proteinaceous receptor, OmpC, the natural S16 receptor. Our work provides evidence that pseudotyping P2 is feasible and can be used to extend the host range of P2 to alternative receptors. Extension of this work could produce alternative chimeric tail fibers to target pathogenic bacterial threats. Our engineering of P2 allows adsorption through a heterologous outer-membrane protein without culturing in its native host, thus providing a potential means of engineering designer phages against pathogenic bacteria from knowledge of their surface proteome.
噬菌体(phages)代表了针对抗生素耐药性细菌感染的强大潜在治疗方法。抗生素耐药细菌对全球健康构成了重大威胁,据估计,导致感染的细菌中有 70% 对一种或多种抗生素具有耐药性。针对数量有限的细胞靶标开发新型抗生素既昂贵又耗时,而且细菌可以迅速产生耐药性。虽然细菌对噬菌体的耐药性可以进化,但细菌对噬菌体的耐药性似乎不会通过横向基因转移传播,噬菌体也可以通过突变类似地适应恢复感染性。已经鉴定出所有已知细菌的噬菌体,允许针对致病菌进行菌株选择性杀伤。在这里,我们对噬菌体 P2 进行了重新设计,以改变其对致病菌的趋向性。通过两种方法设计并生成了 P2 和 S16 基因之间的嵌合尾纤维:基于同源性和文献的方法。通过在 P2 颗粒上呈现嵌合 P2:S16 纤维,我们的数据表明,由此产生的噬菌体有效地从天然 P2 细胞靶标脂多糖脱靶,并能够通过蛋白质受体 OmpC 感染,OmpC 是天然 S16 受体。我们的工作提供了证据,证明假型化 P2 是可行的,可以将 P2 的宿主范围扩展到替代受体。这项工作的扩展可以产生针对致病菌威胁的替代嵌合尾纤维。我们对 P2 的工程设计允许通过异源外膜蛋白进行吸附,而无需在其天然宿主中培养,从而为针对致病菌的工程设计噬菌体提供了一种潜在的方法,这些噬菌体可以利用其表面蛋白质组学的知识进行设计。